eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | cystoid macular dystrophy |
| Comorbidity | C0154841|central retinal vein occlusion |
| Sentences | 32 |
| PubMedID- 21275514 | Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in macular edema with central retinal vein occlusion. |
| PubMedID- 20827142 | Purpose: the purpose of this study was to evaluate the effect of intravitreal triamcinolone acetonide on macular function in cases of macular edema because of central retinal vein occlusion. |
| PubMedID- 22991926 | Retinal function and morphology in central retinal vein occlusion with macular edema. |
| PubMedID- 22562161 | macular edema in central retinal vein occlusion: correlation between optical coherence tomography, angiography and visual acuity. |
| PubMedID- 22105941 | Influence of vitreous factors after vitrectomy for macular edema in patients with central retinal vein occlusion. |
| PubMedID- 21598607 | [medium-term effects of intravitreal bevacizumab for macular edema associated with central retinal vein occlusion]. |
| PubMedID- 25902116 | Recurrent macular edema in central retinal vein occlusion treated with intravitreal ranibizumab using a modified treat and extend regimen. |
| PubMedID- 22424833 | Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. |
| PubMedID- 25634982 | Purpose: the association between aqueous humor levels of various growth/inflammatory factors or cytokines and the severity of macular edema was investigated in patients with central retinal vein occlusion (crvo). |
| PubMedID- 22823029 | Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (vegf), is widely used for the treatment of macular edema associated with central retinal vein occlusion (crvo). |
| PubMedID- 22902212 | Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. |
| PubMedID- 20935688 | Visual improvement in established central retinal vein occlusion with long-standing macular edema following systemic eculizumab treatment. |
| PubMedID- 23046435 | Changes of inflammatory factors after intravitreal triamcinolone acetonide for macular edema with central retinal vein occlusion. |
| PubMedID- 23673531 | Objective: to review the pharmacology, efficacy, and safety data available for aflibercept and compare the drug to other therapeutic options for treatment of macular edema following central retinal vein occlusion (crvo) to determine its likely role in therapy. |
| PubMedID- 21764136 | Objective: to evaluate the safety and efficacy of 1 or 2 treatments with dexamethasone intravitreal implant (dex implant) over 12 months in eyes with macular edema owing to branch or central retinal vein occlusion (brvo or crvo). |
| PubMedID- 23713337 | [ozurdex, modern therapy for macular edema in central retinal vein occlusion]. |
| PubMedID- 23842103 | Purpose: to evaluate the association between vitreous fluid levels of inflammatory factors and macular edema in patients with central retinal vein occlusion (crvo). |
| PubMedID- 26247458 | He developed a central retinal vein occlusion complicated by macular edema and received treatment with intravitreal bevacizumab, which led to resolution of the edema. |
| PubMedID- 25902119 | The purpose of this study was to evaluate the visual and anatomic outcomes of refractory macular edema resulting from ischemic central retinal vein occlusion in patients switched from ranibizumab to aflibercept intravitreal injections. |
| PubMedID- 23379834 | Background: it is unclear how retinal ischemia influences the changes of visual acuity, macular sensitivity, macular thickness, and macular volume after the performance of pars plana vitrectomy (ppv) for macular edema in patients with central retinal vein occlusion (crvo). |
| PubMedID- 22044337 | Rapid resolution of macular edema associated with central retinal vein occlusion using ranibizumab after failure with multiple bevacizumab injections. |
| PubMedID- 24531560 | Association of electroretinogram and morphological findings in central retinal vein occlusion with macular edema. |
| PubMedID- 22925843 | Patients and methods: the present study represents a retrospective review of eight patients presenting with central retinal vein occlusion complicated by macular edema with central foveolar thickness greater than 350 mum by cirrus-oct, zeiss. |
| PubMedID- 19967679 | Purpose: aqueous levels of vascular endothelial growth factor (vegf) and interleukin-6 (il-6) are associated with the severity of macular edema in patients with central retinal vein occlusion (crvo). |
| PubMedID- 23690676 | Unilateral macular edema with central retinal vein occlusion in systemic lupus erythematosus: a case report. |
| PubMedID- 21538003 | Purpose: to investigate the correlation of soluble intercellular adhesion molecule 1 (sicam-1) and vascular endothelial growth factor (vegf) with macular edema in patients with central retinal vein occlusion (crvo). |
| PubMedID- 25576994 | Purpose: to review the available evidence regarding the safety and efficacy of therapies for the treatment of macular edema (me) associated with central retinal vein occlusion (crvo). |
| PubMedID- 25383828 | Results: initial ophthalmic examination showed bilateral central retinal vein occlusion with macular edema, including serous macular detachment in the left eye. |
| PubMedID- 24847256 | We report a 19-year-old patient who developed a central retinal vein occlusion (crvo) with significant macular edema and visual impairment following intense exercise and dehydration. |
| PubMedID- 24084497 | Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 galileo study. |
| PubMedID- 20453544 | The outcome of vitrectomy for macular edema was examined in patients with central retinal vein occlusion (crvo), as well as whether vascular endothelial growth factor (vegf) and interleukin-6 (il-6) levels in vitreous fluid influence the visual prognosis and macular edema. |
| PubMedID- 20658459 | The patients were divided into the 3 following groups: group 1 (nonproliferative diabetic retinopathy), group 2 (choroidal neovascularization secondary to age-related macular degeneration), and group 3 (macular edema with branch or central retinal vein occlusion). |
Page: 1